• Adaptyv Bio raised a USD 40 million Series A led by Highland Europe, with participation from Ace & Company SA’s ACE Ventures.
• ACE Ventures also led Adaptyv’s USD 8 million seed round in November 2024, marking a follow-on investment in the Series A.
• Adaptyv runs an automated protein-validation lab that turns digital protein sequences into experimental binding data through a web platform and API.
• Funding targets capacity expansion through 2027, including a London lab and office planned for Q4 2026 alongside a Lausanne expansion.
• Adaptyv plans to broaden workflows beyond binding into developability and full biophysical characterization to support larger drug-discovery programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ace & Company SA published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.